Contact Us
Drug Search Results
More Filters [+]

ASP-3662

Alternative Names: asp-3662, asp3662, asp 3662
Latest Update: 2024-08-09
Latest Update Note: News Article

Product Description

ASP3662 is a potent and selective inhibitor of 11_-HSD1.

Mechanisms of Action: 11beta-HSD1 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ASP-3662

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Peripheral Nervous System Diseases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
3662-CL-0049

P2

Terminated

Peripheral Nervous System Diseases

2016-05-20

30%
3662-CL-0011

P1

Completed

Healthy Volunteers

2016-05-01

Recent News Events

Date

Type

Title

08/09/2024

News Article

 Peripheral Neuropathy Treatment Market size is set to grow by USD 447.3 million from 2024-2028, Increasing prevalence of peripheral neuropathy boost the market, Technavio

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions